Eintrag weiter verarbeiten
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 26, 2008, 32, S. 5175-5182 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Devizzi, Liliana Guidetti, Anna Tarella, Corrado Magni, Michele Matteucci, Paola Seregni, Ettore Chiesa, Carlo Bombardieri, Emilio Di Nicola, Massimo Carlo-Stella, Carmelo Gianni, Alessandro M. Devizzi, Liliana Guidetti, Anna Tarella, Corrado Magni, Michele Matteucci, Paola Seregni, Ettore Chiesa, Carlo Bombardieri, Emilio Di Nicola, Massimo Carlo-Stella, Carmelo Gianni, Alessandro M. |
|---|---|
| author |
Devizzi, Liliana Guidetti, Anna Tarella, Corrado Magni, Michele Matteucci, Paola Seregni, Ettore Chiesa, Carlo Bombardieri, Emilio Di Nicola, Massimo Carlo-Stella, Carmelo Gianni, Alessandro M. |
| spellingShingle |
Devizzi, Liliana Guidetti, Anna Tarella, Corrado Magni, Michele Matteucci, Paola Seregni, Ettore Chiesa, Carlo Bombardieri, Emilio Di Nicola, Massimo Carlo-Stella, Carmelo Gianni, Alessandro M. Journal of Clinical Oncology High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation Cancer Research Oncology |
| author_sort |
devizzi, liliana |
| spelling |
Devizzi, Liliana Guidetti, Anna Tarella, Corrado Magni, Michele Matteucci, Paola Seregni, Ettore Chiesa, Carlo Bombardieri, Emilio Di Nicola, Massimo Carlo-Stella, Carmelo Gianni, Alessandro M. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.16.8294 <jats:sec><jats:title>Purpose</jats:title><jats:p> To develop high-dose myeloablative therapy for CD20<jats:sup>+</jats:sup> non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients with relapsed/refractory (n = 25) or de novo high-risk (n = 5) NHL received one myeloablative dose of yttrium-90 (<jats:sup>90</jats:sup>Y)–ibritumomab tiuxetan after five chemotherapy courses, including three cycles of anthracycline- or platinum-containing regimens, one cycle of cyclophosphamide (4 to 7 g/m<jats:sup>2</jats:sup>), and one cycle of cytarabine (12 to 24 g/m<jats:sup>2</jats:sup>). The only exclusion criteria were CNS lymphoma and Eastern Cooperative Oncology Group performance status of more than 3. Primary end points were overall survival (OS) and event-free survival (EFS). Secondary end points included safety and applicability of high-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. To minimize hematologic toxicity, stem cells were reinfused at days 7 and 14 after <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients received <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan 0.8 mCi/kg, and 17 patients received 1.2 mCi/kg. At 1.2 mCi/kg, the radiation absorbed by critical nonhematologic organs approached the protocol-defined upper safety limit, defining this as the recommended dose for subsequent studies. Hematologic toxicity was mild to moderate and of short duration. Infections occurred in 27% of patients (none had a severity grade greater than 3). After a median observation time of 30 months (range, 22 to 48 months), no myeloid secondary malignancy or chromosomal abnormality was observed, the OS rate was 87%, and the EFS rate was 69%. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan seems to be an innovative myeloablative regimen with unprecedented short-term toxicity and wide applicability. Further studies are required to assess its long-term safety and role in the management of CD20<jats:sup>+</jats:sup> NHL. </jats:p></jats:sec> High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2008.16.8294 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xNi44Mjk0 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xNi44Mjk0 |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Clinical Oncology (ASCO), 2008 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2008 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
devizzi2008highdoseyttrium90ibritumomabtiuxetanwithtandemstemcellreinfusionanoutpatientpreparativeregimenforautologoushematopoieticcelltransplantation |
| publishDateSort |
2008 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_unstemmed |
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_full |
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_fullStr |
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_full_unstemmed |
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_short |
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_sort |
high-dose yttrium-90–ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2008.16.8294 |
| publishDate |
2008 |
| physical |
5175-5182 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> To develop high-dose myeloablative therapy for CD20<jats:sup>+</jats:sup> non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients with relapsed/refractory (n = 25) or de novo high-risk (n = 5) NHL received one myeloablative dose of yttrium-90 (<jats:sup>90</jats:sup>Y)–ibritumomab tiuxetan after five chemotherapy courses, including three cycles of anthracycline- or platinum-containing regimens, one cycle of cyclophosphamide (4 to 7 g/m<jats:sup>2</jats:sup>), and one cycle of cytarabine (12 to 24 g/m<jats:sup>2</jats:sup>). The only exclusion criteria were CNS lymphoma and Eastern Cooperative Oncology Group performance status of more than 3. Primary end points were overall survival (OS) and event-free survival (EFS). Secondary end points included safety and applicability of high-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. To minimize hematologic toxicity, stem cells were reinfused at days 7 and 14 after <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients received <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan 0.8 mCi/kg, and 17 patients received 1.2 mCi/kg. At 1.2 mCi/kg, the radiation absorbed by critical nonhematologic organs approached the protocol-defined upper safety limit, defining this as the recommended dose for subsequent studies. Hematologic toxicity was mild to moderate and of short duration. Infections occurred in 27% of patients (none had a severity grade greater than 3). After a median observation time of 30 months (range, 22 to 48 months), no myeloid secondary malignancy or chromosomal abnormality was observed, the OS rate was 87%, and the EFS rate was 69%. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan seems to be an innovative myeloablative regimen with unprecedented short-term toxicity and wide applicability. Further studies are required to assess its long-term safety and role in the management of CD20<jats:sup>+</jats:sup> NHL. </jats:p></jats:sec> |
| container_issue |
32 |
| container_start_page |
5175 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
26 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339234805252107 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:44:37.494Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=High-Dose+Yttrium-90%E2%80%93Ibritumomab+Tiuxetan+With+Tandem+Stem-Cell+Reinfusion%3A+An+Outpatient+Preparative+Regimen+for+Autologous+Hematopoietic+Cell+Transplantation&rft.date=2008-11-10&genre=article&issn=1527-7755&volume=26&issue=32&spage=5175&epage=5182&pages=5175-5182&jtitle=Journal+of+Clinical+Oncology&atitle=High-Dose+Yttrium-90%E2%80%93Ibritumomab+Tiuxetan+With+Tandem+Stem-Cell+Reinfusion%3A+An+Outpatient+Preparative+Regimen+for+Autologous+Hematopoietic+Cell+Transplantation&aulast=Gianni&aufirst=Alessandro+M.&rft_id=info%3Adoi%2F10.1200%2Fjco.2008.16.8294&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339234805252107 |
| author | Devizzi, Liliana, Guidetti, Anna, Tarella, Corrado, Magni, Michele, Matteucci, Paola, Seregni, Ettore, Chiesa, Carlo, Bombardieri, Emilio, Di Nicola, Massimo, Carlo-Stella, Carmelo, Gianni, Alessandro M. |
| author_facet | Devizzi, Liliana, Guidetti, Anna, Tarella, Corrado, Magni, Michele, Matteucci, Paola, Seregni, Ettore, Chiesa, Carlo, Bombardieri, Emilio, Di Nicola, Massimo, Carlo-Stella, Carmelo, Gianni, Alessandro M., Devizzi, Liliana, Guidetti, Anna, Tarella, Corrado, Magni, Michele, Matteucci, Paola, Seregni, Ettore, Chiesa, Carlo, Bombardieri, Emilio, Di Nicola, Massimo, Carlo-Stella, Carmelo, Gianni, Alessandro M. |
| author_sort | devizzi, liliana |
| container_issue | 32 |
| container_start_page | 5175 |
| container_title | Journal of Clinical Oncology |
| container_volume | 26 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> To develop high-dose myeloablative therapy for CD20<jats:sup>+</jats:sup> non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients with relapsed/refractory (n = 25) or de novo high-risk (n = 5) NHL received one myeloablative dose of yttrium-90 (<jats:sup>90</jats:sup>Y)–ibritumomab tiuxetan after five chemotherapy courses, including three cycles of anthracycline- or platinum-containing regimens, one cycle of cyclophosphamide (4 to 7 g/m<jats:sup>2</jats:sup>), and one cycle of cytarabine (12 to 24 g/m<jats:sup>2</jats:sup>). The only exclusion criteria were CNS lymphoma and Eastern Cooperative Oncology Group performance status of more than 3. Primary end points were overall survival (OS) and event-free survival (EFS). Secondary end points included safety and applicability of high-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. To minimize hematologic toxicity, stem cells were reinfused at days 7 and 14 after <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients received <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan 0.8 mCi/kg, and 17 patients received 1.2 mCi/kg. At 1.2 mCi/kg, the radiation absorbed by critical nonhematologic organs approached the protocol-defined upper safety limit, defining this as the recommended dose for subsequent studies. Hematologic toxicity was mild to moderate and of short duration. Infections occurred in 27% of patients (none had a severity grade greater than 3). After a median observation time of 30 months (range, 22 to 48 months), no myeloid secondary malignancy or chromosomal abnormality was observed, the OS rate was 87%, and the EFS rate was 69%. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan seems to be an innovative myeloablative regimen with unprecedented short-term toxicity and wide applicability. Further studies are required to assess its long-term safety and role in the management of CD20<jats:sup>+</jats:sup> NHL. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2008.16.8294 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xNi44Mjk0 |
| imprint | American Society of Clinical Oncology (ASCO), 2008 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2008 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T15:44:37.494Z |
| match_str | devizzi2008highdoseyttrium90ibritumomabtiuxetanwithtandemstemcellreinfusionanoutpatientpreparativeregimenforautologoushematopoieticcelltransplantation |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 5175-5182 |
| publishDate | 2008 |
| publishDateSort | 2008 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Devizzi, Liliana Guidetti, Anna Tarella, Corrado Magni, Michele Matteucci, Paola Seregni, Ettore Chiesa, Carlo Bombardieri, Emilio Di Nicola, Massimo Carlo-Stella, Carmelo Gianni, Alessandro M. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.16.8294 <jats:sec><jats:title>Purpose</jats:title><jats:p> To develop high-dose myeloablative therapy for CD20<jats:sup>+</jats:sup> non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients with relapsed/refractory (n = 25) or de novo high-risk (n = 5) NHL received one myeloablative dose of yttrium-90 (<jats:sup>90</jats:sup>Y)–ibritumomab tiuxetan after five chemotherapy courses, including three cycles of anthracycline- or platinum-containing regimens, one cycle of cyclophosphamide (4 to 7 g/m<jats:sup>2</jats:sup>), and one cycle of cytarabine (12 to 24 g/m<jats:sup>2</jats:sup>). The only exclusion criteria were CNS lymphoma and Eastern Cooperative Oncology Group performance status of more than 3. Primary end points were overall survival (OS) and event-free survival (EFS). Secondary end points included safety and applicability of high-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. To minimize hematologic toxicity, stem cells were reinfused at days 7 and 14 after <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients received <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan 0.8 mCi/kg, and 17 patients received 1.2 mCi/kg. At 1.2 mCi/kg, the radiation absorbed by critical nonhematologic organs approached the protocol-defined upper safety limit, defining this as the recommended dose for subsequent studies. Hematologic toxicity was mild to moderate and of short duration. Infections occurred in 27% of patients (none had a severity grade greater than 3). After a median observation time of 30 months (range, 22 to 48 months), no myeloid secondary malignancy or chromosomal abnormality was observed, the OS rate was 87%, and the EFS rate was 69%. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High-dose <jats:sup>90</jats:sup>Y-ibritumomab tiuxetan seems to be an innovative myeloablative regimen with unprecedented short-term toxicity and wide applicability. Further studies are required to assess its long-term safety and role in the management of CD20<jats:sup>+</jats:sup> NHL. </jats:p></jats:sec> High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation Journal of Clinical Oncology |
| spellingShingle | Devizzi, Liliana, Guidetti, Anna, Tarella, Corrado, Magni, Michele, Matteucci, Paola, Seregni, Ettore, Chiesa, Carlo, Bombardieri, Emilio, Di Nicola, Massimo, Carlo-Stella, Carmelo, Gianni, Alessandro M., Journal of Clinical Oncology, High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation, Cancer Research, Oncology |
| title | High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_full | High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_fullStr | High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_full_unstemmed | High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_short | High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| title_sort | high-dose yttrium-90–ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation |
| title_unstemmed | High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2008.16.8294 |